What problem does this paper attempt to address?

### What problems does this paper attempt to solve? This paper aims to optimize the dosage of micafungin in patients with sepsis in Chinese intensive care units (ICUs) through population pharmacokinetic - pharmacodynamic (PK - PD) analysis. Specifically, the research objectives include: 1. **Identify parameters affecting the pharmacokinetics of micafungin**: Determine which factors will affect the in - vivo metabolism and distribution of micafungin in Chinese ICU patients. 2. **Optimize the dosage of micafungin**: By calculating the probability of achieving pharmacodynamic targets, determine the appropriate micafungin dosage to ensure the effectiveness and safety of the drug. ### Research background and importance Invasive candidiasis (ICI) is a high - risk opportunistic infection in the ICU, especially in patients receiving broad - spectrum antibiotics or total parenteral nutrition, and those who have undergone abdominal surgery. In recent years, due to the high cost of ICI treatment and the mortality rate as high as 35% - 80%, the timely use of appropriate antifungal drugs has become particularly important. The guidelines revised by the Infectious Diseases Society of America (IDSA) in 2016 strongly recommend starting empirical antifungal treatment as early as possible in ICU patients with ICI risk factors and septic shock. Echinocandin drugs (such as micafungin) have become the first - choice drugs for treating candidiasis because of their better efficacy against fluconazole - resistant Candida species. However, studies have shown that the exposure of micafungin varies significantly under different pathophysiological conditions, especially lower in ICU patients. Therefore, PK - PD studies for Chinese ICU patients are needed to optimize the dosage of micafungin and improve clinical efficacy. ### Research methods and results 1. **Sample collection and analysis**: Blood samples were collected from 32 Chinese ICU patients to establish a population pharmacokinetic model, and Monte Carlo simulation was used to evaluate the probability of reaching an appropriate plasma level. 2. **Analysis of influencing factors**: It was found that alanine aminotransferase (ALT) and Sequential Organ Failure Assessment (SOFA) scores significantly affected the clearance rate and peripheral distribution volume of micafungin. 3. **Dose optimization**: Based on the ratio of the area under the 24 - hour curve (AUC 0 - 24 h) to the minimum inhibitory concentration (MIC) (AUC 0 - 24 h/MIC), Monte Carlo simulation results showed that, in order to achieve a target attainment probability (PTA) of ≥90%, the recommended daily dosages for different Candida species are: - For *Candida glabrata* and *Candida tropicalis*, at least 200 mg and 250 mg respectively. - For *Candida krusei* and *Candida parapsilosis*, even with a daily dose of 300 mg, it is difficult to achieve a PTA of ≥90%. ### Conclusion The currently recommended daily dose of 100 mg of micafungin may result in a lower clinical success rate in non - *Candida albicans* infections; therefore, the dose should be increased to improve clinical outcomes. These findings contribute to personalized treatment regimens and improve the efficacy of micafungin in treating candidiasis in Chinese ICU patients. ### Formula representation The formulas involved in the paper are as follows: 1. **Estimation of individual pharmacokinetic parameters**: \[ P_i = TV(P)\cdot e^{\eta_i} \] where \(P_i\) is the individual's pharmacokinetic parameter estimate, \(TV(P)\) is the typical value of the study population, and \(\eta_i\) represents the inter - individual variability (IIV) with a mean of 0 and a variance of \(\omega^2\). 2. **Residual error model**: - Additive error model: \[ C_{\text{obs},ij}=C_{\text{pre},ij}+\varepsilon_{ij1} \] - Proportional error model: \[ C_{\text{obs}

Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis

Evaluation of Population Pharmacokinetic Models of Micafungin: Implications for Dosing Regimen Optimization in Critically Ill Patients

Population pharmacokinetics and dosing simulations of meropenem in septic critically ill patients with complicated intra-abdominal infection or pneumonia

Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis

Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection

Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study

Population Pharmacokinetics, Dosing Optimization and Clinical Outcomes of Biapenem in Patients with Sepsis

Pharmacist-driven Antimicrobial Stewardship in Intensive Care Units in East China: A Multicenter Prospective Cohort Study

Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step Toward Dose Optimization Using Monte Carlo Simulation.

Lefamulin Dosing Optimization Using Population Pharmacokinetic and Pharmacokinetic/pharmacodynamic Assessment in Chinese Patients with Community-Acquired Bacterial Pneumonia

Optimization of Voriconazole Dosage Regimen to Improve the Efficacy in Patients with Invasive Fungal Disease by Pharmacokinetic/pharmacodynamic Analysis

Dose Optimization of Piperacillin/tazobactam in Patients with Renal Dysfunction Based on Population Pharmacokinetic and Pharmacodynamic Simulations

Assessment of micafungin dosage regimens against Candida spp. in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation

[Study on the Optimization of Administration Regimen of Vancomycin in Critical Patients].

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations.

Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients

Population Pharmacokinetics and Model-Based Dosing Optimization of Teicoplanin in Pediatric Patients

Pharmacodynamic Target Attainment of Seven Antimicrobials Against Gram-negative Bacteria Collected from China in 2003 and 2004.

Identification of Factors Influencing the Pharmacokinetics of Voriconazole and the Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients with Invasive Fungal Infections

Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis

Model-based Evaluation of the Clinical and Microbiological Efficacy of Vancomycin: A Prospective Study of Chinese Adult In-house Patients